Shield Therapeutics (STX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 2.75p
   
  • Change Today:
      0.000p
  • 52 Week High: 7.65
  • 52 Week Low: 1.23
  • Currency: UK Pounds
  • Shares Issued: 782.06m
  • Volume: 640,215
  • Market Cap: £21.51m
  • Beta: 1.81

Fundamentals - based on IFRS

  $ (Millions) $ (Millions) $ (Millions) £ (Millions) £ (Millions)
Income Statement 30-Jun-24 30-Jun-23 30-Jun-22 30-Jun-21 30-Jun-20
Continuing Operations          
Revenue 12.13 3.74 2.61 0.48 8.92
Operating Profit/(Loss) (14.06) (11.54) (15.04) (7.64) 2.39
Profit Before Tax (15.48) (11.79) (14.66) (7.58) 2.75
Profit After Tax (15.48) (12.60) (15.12) (7.28) 3.12
Discontinued Operations          
Profit After Tax n/a n/a n/a n/a n/a
PROFIT FOR THE PERIOD (15.48) (12.60) (15.12) (7.28) 3.12
           
Continuing EPS          
Earnings per Share - Basic (0.020¢) (0.020¢) (1.52¢) (0.87p) 0.55p
Earnings per Share - Diluted (0.020¢) (0.020¢) (1.52¢) (0.87p) 0.55p
Earnings per Share - Adjusted (0.020¢) (0.020¢) (1.52¢) (0.87p) 0.55p
Continuing and Discontinued EPS          
Earnings per Share - Basic (0.020¢) (0.020¢) (1.52¢) (0.87p) 0.55p
Earnings per Share - Diluted (0.020¢) (0.020¢) (1.52¢) (0.87p) 0.55p
Earnings per Share - Adjusted (0.020¢) (0.020¢) (1.52¢) (0.87p) 0.55p
Dividend per Share n/a n/a n/a n/a n/a
  $ (Millions) $ (Millions) $ (Millions) £ (Millions) £ (Millions)
Balance Sheet 30-Jun-24 30-Jun-23 30-Jun-22 30-Jun-21 30-Jun-20
Total Non-Current Assets 18.92 15.57 33.28 26.08 28.65
Net Current Assets cn/a cn/a cn/a cn/a cn/a
Total Assets 46.76 41.67 43.62 52.41 38.24
Total Liabilities 46.22 14.56 3.96 1.39 2.77
Net Assets 0.54 27.10 39.67 51.01 35.47
           
Shareholders Funds 0.54 27.10 39.67 51.01 35.47
Minority Interests/Other Equity n/a n/a n/a n/a n/a
Total Equity 0.54 27.10 39.67 51.01 35.47

Key

* GAAP

a. Includes discontinued activities

b. Including assets due in more than one year

c. Not disclosed under IFRS

d. Total fixed assets

e. Includes borrowings

f. Included in cash flow from operating activities under IFRS

g. Included in net cash from investing activities under IFRS

h. Pre-tax

i. Capital expenditure

j. Based on operating cash flow before tax

k. Issue of ordinary shares

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: Forecast figures based on normalised accounts.

 

Top of Page